RAD Achieves Partial Response in Phase 1 Trial of RAD204
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The trial has shown that one patient achieved a significant reduction in tumor size and remains progression-free beyond seven months. Both patients treated in the third cohort of the trial have demonstrated favorable safety and tolerability, with no dose-limiting toxicities observed.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Radiopharm Theranostics Limited on 6ix
In the deck
Story so far
- Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026
- Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases
- RAD Completes Enrollment in Phase 2b Trial of RAD 101
Earlier from Radiopharm Theranostics
- Radiopharm Theranostics Reports Business Update
- Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026
- Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases
- RAD Completes Enrollment in Phase 2b Trial of RAD 101
- Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Later from Radiopharm Theranostics
- Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
- RAD completes A$12.5 M placement and launches A$6 M SPP
- Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
- Application for quotation of securities - RAD
- Notice Under Section 708A
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics